

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known Application Number 10/522,207 Filing Date October 27, 2005 First Named Inventor Mezher Ali et al. Art Unit 1625 Examiner Name Celia C. Chang	
(Use as many sheets as necessary)					
Sheet	1	of	1	Attorney Docket No: AC-22-US	

US PATENT DOCUMENTS					
Examiner Initials*	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
					T ²

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/CC/		SILVA, et al., Advances in Prodrug Design, Mini-Reviews in Medicinal Chemistry, 2005, Vol. 5, pp. 893-914.			
/CC/		WU, W. et al., Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug, J. Med. Chem., 2007, Vol. 50(15), pp. 3743-3746.			
/CC/		YILDIZ, Y. et al., Mutation of β-glucosidase 2 causes glycolipid storage disease and impaired male fertility, The Journal of Clinical Investigation, 2006, Vol. 116, No. 11, pp. 2985-2994.			

EXAMINER	/Celia Chang/	DATE CONSIDERED	10/26/2009
----------	---------------	-----------------	------------

Substitute Disclosure Statement Form (PTO-1449)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant + Applicant's unique citation designation number (optional) + Applicant is to place a check mark here if English language Translation is attached